Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 40, Pages 16101-16106
Publisher
Proceedings of the National Academy of Sciences
Online
2012-09-18
DOI
10.1073/pnas.1211023109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR
- (2012) S. A. Kazane et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
- (2011) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Selective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
- (2011) Benjamin M. Hutchins et al. CHEMISTRY & BIOLOGY
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
- (2011) Robert Y. Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Site-Specific Coupling and Sterically Controlled Formation of Multimeric Antibody Fab Fragments with Unnatural Amino Acids
- (2011) Benjamin M. Hutchins et al. JOURNAL OF MOLECULAR BIOLOGY
- Targeting activated integrin αvβ3 with patient-derived antibodies impacts late-stage multiorgan metastasis
- (2010) Karin Staflin et al. CLINICAL & EXPERIMENTAL METASTASIS
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2010) J. R. Junutula et al. CLINICAL CANCER RESEARCH
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
- (2009) A. Hollestelle et al. CANCER RESEARCH
- MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
- (2009) Ann F. Chambers CANCER RESEARCH
- An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli
- (2009) Travis S. Young et al. JOURNAL OF MOLECULAR BIOLOGY
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
- (2008) Svetlana O. Doronina et al. BIOCONJUGATE CHEMISTRY
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
- (2008) E. Oflazoglu et al. CLINICAL CANCER RESEARCH
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started